291. Hirschsprung disease, entire colon type
13 clinical trials,   32 drugs   (DrugBank: 15 drugs),   0 gene,   0 pathway

Searched query = "Hirschsprung disease, entire colon type", "Hirschsprung disease, small intestine type", "Hirschsprung disease", "Hirschprung disease", "Hirschsprung disease associated entercolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000024993
2016/12/0115/12/2016Study for efficacy of usage of enteral nutrient with immuno-balance modulation action in perioperative management of pediatric patients Hirschsprung's disease, Atresia ani, Congenital biliary dilatation, GERDIn the control group, the following enteral nutrient will be administered (breast milk or artificial milk for infants, Racol for infants).
Dose and duration: Before surgery, the patient will take enteral nutrients at 60 to 100 kcal / kg per day for 3 days. After the surgery, enteral nutrition will restart within 2 to 3 days after surgery, and continue until 6th postoperative day.
In contrast, immunomodulatory nutrition is administered in the test group.
Dose and duration: Before surgery, the patient will take enteral nutrients at 60 to 100 kcal / kg per day for 3 days. After the surgery, enteral nutrition will restart within 2 to 3 days after surgery, and continue until 6th postoperative day.

The study period is from December 1, 2016 to March 31, 2018.
University of Tsukuba HospitalNULLPending6months-old48months-oldMale and Female10Not applicableJapan